Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

ROS1 gene rearrangements have been reported in diverse cancer types including non‐small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma. The tyrosine kinase inhibitors, crizotinib, lorlatinib, and entrectinib, have demonstrated favorable efficacy in treating ROS...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Meiying, Han, Yuchen, Li, Pan, Zhang, Jianying, Ou, Qiuxiang, Tong, Xiaoling, Zhao, Ruiying, Dong, Nan, Wu, Xue, Li, Wencai, Jiang, Guozhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607175/
https://www.ncbi.nlm.nih.gov/pubmed/32871626
http://dx.doi.org/10.1002/1878-0261.12789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607175/
https://www.ncbi.nlm.nih.gov/pubmed/32871626
http://dx.doi.org/10.1002/1878-0261.12789

Ejemplares similares